Besides COVID-19, type 2 diabetes is the most pressing healthcare problem faced by many right now. In the UK, it is estimated that one in 10 people over the age of 40 is diagnosed with type 2 diabetes. Of these, 60 percent are said to suffer from a complication of the disease along with major risks, including amputation, heart attack, and stroke.

The company provides digital prediabetes and type 2 diabetes remission programmes that help patients to reverse disease and live medication-free. Habitual will use the proceeds to fuel user growth, increase team size, and undertake clinical research trials.

London’S Healthtech Habitual Specialising In Diabetes Reversal Closes £1.7M Funding To Take Up Clinical Trials

London’S Healthtech Habitual Specialising In Diabetes Reversal Closes £1.7M Funding To Take Up Clinical Trials

Company Info